REFERENCES:

Ovarian ablation for early breast cancer. Early Breast Cancer Trialists’ Collaborative Group. Cochrane Database Syst Rev. 2000;CD000485. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996;348:1189-1196. Abstract

Baum M et al. Management of premenopausal women with early breast cancer: Is there a role for goserelin? Proc ASCO 2001; Abstract 103.

Berglund G et al. Effect of endocrine treatment on sexuality in pre-menopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2001;19:2788-96. Abstract

Boccardo F et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian B reast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718-27. Abstract

Boccardo F et al. LHRH-agonist (LHRH-A) + tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): Results of a meta-analysis of four trials. Proc ASCO 1999; Abstract 416.

Celio L et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 1999;19:2261-8. Abstract

Cheung KL et al. The combined use of goserelin and anastrozole as second line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects. Proc ASCO 2001; Abstract 1937.

Crucitta E et al. New aromatase inhibitors in the treatment of advanced breast cancer. Int J Oncol 2000;17:1037-41. Abstract

Davidson N et al. Effect of chemohormonal therapy in pre-menopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101). Proc ASCO 1999; Abstract 249A, 67A.

de Haes H et al. Early benefits in quality of life (QoL) observed in zoladex-treated versus CMF-treated pre-/perimenopausal patients with node-positive early breast cancer. Proc ASCO 2001; Abstract 138.

Dowsett M et al. Vorozole results in greater estrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 1999;56:25-34. Abstract

Forward D et al. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000; Abstract 582.

Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94. Abstract

Henderson IC. Ovarian ablation comes around again. Breast Diseases: A Year Book Quarterly 2000;11(2):117-120. No abstract available.

Hisamatsu K et al. A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist. Gan To Kagaku Ryoho 1997;24:1327-30. Abstract

Hoffken K, Kath R. The role of LH-RH analogues in the adjuvant and palliative treatment of breast cancer. Recent Results Cancer Res 2000;153:61-70. Abstract

Houghton J et al. The ZIPP trial of adjuvant Zoladex in premenopausal patients with early breast cancer: An update at five years. Proc ASCO 2000; Abstract 359.

Ingle JN et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999;5(7):1642-9. Abstract

Ingle JN et al. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 1999;6:265-9. Abstract

Jakesz R. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proc ASCO 1999; Abstract 250.

Klijn JG et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 2000;92:903-11. Abstract

Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53. Abstract

Martinetti A et al. The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: Effects on bone metabolism markers. J Steroid Biochem Mol Biol 2000;75:65-73. Abstract

Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging 2000;16:261-71. Abstract

Michaud LB et al. Combination endocrine therapy in the management of breast cancer. Oncologist 2001;6(6):538-546. Abstract

Nystedt M et al. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer—self-rated physiological effects and symptoms. Acta Oncol 2000;39(8):959-68. Abstract

Pritchard KI. Current and future directions in medical therapy for breast carcinoma: Endocrine treatment. Cancer 2000;88:3065-72. Abstract

Rose C et al. Combined endocrine treatment of elderly post-menopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Res Treat 2000;61(2):103-10. Abstract

Rutqvist LE. Zoladex® and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (C. R. C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G. I. V. I. O). Proc ASCO 1999; Abstract 251.

Sverrisdottir A et al. Bone mineral density in premenopausal patients in a randomized trial of adjuvant endocrine therapy (ZIPP-TRIAL). Proc ASCO 2001; Abstract 96.

Back | Top of Page